Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA

Core Points - Genentech has commenced construction on its first manufacturing facility on the East Coast, located in Holly Springs, North Carolina, which will support the production of metabolic medicines, including obesity treatments [1][2] - The initial investment for this facility exceeds $700 million and is part of Roche's broader commitment of $50 billion towards US manufacturing infrastructure and R&D [2][8] - The facility is projected to create over 1,900 jobs and is strategically located in a growing biopharmaceutical hub with access to a skilled workforce and leading academic institutions [2][8] - The new site will be completed and operational by 2029, featuring modern biomanufacturing technologies and advanced automation [3] - Designed for high-volume and sustainable production, the facility will enhance Roche's manufacturing capacity and supply chain resilience, complementing existing sites globally [4][8] Company Overview - Roche, founded in 1896, is the world's largest biotechnology company and a leader in in-vitro diagnostics, focusing on developing innovative medicines and diagnostics [5] - Sustainability has been a core aspect of Roche's operations for over 125 years, with commitments to achieve net zero by 2045 [6]